Comparing SG&A Expenses: Catalent, Inc. vs ImmunityBio, Inc. Trends and Insights

A Tale of Two Companies: Catalent, Inc. vs ImmunityBio, Inc.

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial health of companies is crucial. Catalent, Inc. and ImmunityBio, Inc. offer a fascinating study in contrasts when it comes to their Selling, General, and Administrative (SG&A) expenses over the past decade.

From 2014 to 2023, Catalent's SG&A expenses have shown a robust upward trend, increasing by approximately 180%. This growth reflects the company's strategic investments in expanding its market reach and operational capabilities. In contrast, ImmunityBio's SG&A expenses have been more volatile, peaking in 2015 and then stabilizing at lower levels. This fluctuation could indicate a more cautious approach to scaling operations or a focus on cost efficiency.

As we look to 2024, Catalent's expenses continue to rise, while ImmunityBio's data remains incomplete, leaving room for speculation on its future trajectory.